Macular function after intravitreal triamcinolone acetonide injection for diabetic macular oedema.
OBJECTIVE
We aimed to evaluate the effect of intravitreal triamcinolone acetonide (IVTA) on macular function in patients with diabetic macular oedema (DMO).


METHODS
Eleven eyes in 11 patients with DMO were enrolled. In each eye, at baseline and at 30 days after IVTA injection, logMAR visual acuity (VA), macular sensitivity, fixation stability and fixation location by MP-1 microperimetry and optical coherence tomography (OCT) foveal thickness were assessed.


RESULTS
Thirty days after IVTA injection, eyes with DMO showed a significant (p<0.001) reduction in foveal thickness and significant (p<0.01) increases in logMAR VA and MP-1 retinal sensitivity (p<0.001). There was also significant (p=0.046) improvement in fixation location and some improvement in fixation stability, although the latter was not significant (p=0.08).


CONCLUSIONS
In eyes with DMO, short-term improvement in retinal sensitivity and fixation properties can be achieved by IVTA injection.
Karacorlu
Murat
M
Istanbul Retina Institute Inc., Istanbul, Turkey. retina@pobox.com
Ozdemir
Hakan
H
Senturk
Fevzi
F
Karacorlu
Serra Arf
SA
Uysal
Omer
O
D000368:Aged; D003924:Diabetes Mellitus, Type 2; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007267:Injections; D008266:Macula Lutea / Q000503:physiopathology*; D008269:Macular Edema / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D014792:Visual Acuity / Q000502:physiology; D058609:Visual Field Tests; D014822:Vitreous Body
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide